Glycyrrhizin as a Potential Treatment for the Novel Coronavirus (COVID-19)

Title:Glycyrrhizin as a Potential Treatment for the Novel Coronavirus (COVID-19)

Volume: 21 Issue: 16

Author(s): Habeb Al-Kamel*Oliver Grundmann

Affiliation:

• Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL,United States

Keywords: Coronavirus, SARS-COV-2, COVID-19, glycyrrhizin, broad-spectrum antiviral agent, licorice Root.

Abstract: COVID-19 is an emerging viral infection of zoonotic origin that is closely related to the severe acute respiratory syndrome coronavirus (SARS-CoV) that caused an outbreak in 2003. Therefore, scientists named the new virus SARS-CoV-2. On March 11, 2020, The World Health Organization (WHO) recognized COVID-19 as a global pandemic. At present, three vaccines have been approved or are being considered for approval by national regulatory agencies to immunize against COVID- 19. However, the vaccines do not remain widely available, and no specific treatment against the virus is available. The pathogenesis and proliferation pathways of SARS-CoV-2 are still not well known. Thus, in this article, the saponin glycyrrhizin is discussed as a new potential therapeutic agent of natural origin (licorice root, Glycyrrhiza glabra) for the potential treatment of COVID-19 infections.

Cite this article as:

Al-Kamel Habeb *, Grundmann Oliver , Glycyrrhizin as a Potential Treatment for the Novel Coronavirus (COVID-19), Mini-Reviews in Medicinal Chemistry 2021; 21 (16) . https://dx.doi.org/10.2174/1389557521666210210160237